Sedana Medical AB (publ) announced that the enrollment of the planned 700 patients in the SESAR trial has been completed. The trial Sevoflurane for Sedation in Acute Respiratory Distress Syndrome: A Multicenter prospective Randomized Trial (SESAR) is an investigator-initiated trial (IIT) that is supported in part by Sedana Medical and by the French Ministry of Health. The SESAR trial, comparing sevoflurane via the Sedaconda ACD with intravenous propofol for up to 7 days is led by professor Matthieu Jabaudon and his team from Clermont Ferrand, France.

The patient population consists of 700 adult patients with moderate to severe acute respiratory failure. The primary endpoint is ventilator-free days up to day 28 from randomization. Secondary endpoints include changes in pulmonary and other organ functions.

The same research group published pilot study results in 2017, which led to this larger study, designed to corroborate the preliminary findings of the pilot. The work with data curation and analysis is expected to take at least until second half-year of 2024. Sedana Medical will not be involved in analysing the results.